Dentons and Latham & Watkins advised ATAI Life Sciences on the deal.
ATAI Life Sciences closed a $125 million Series C financing round. Founding investor Apeiron Investment Group led the round together with Peter Thiel and Catalio Capital Management. Other existing investors such as Future Ventures and Galaxy Investment Partners as well as new investors such as Falcon Edge Capital and Pura Vida Pro were also involved. ATAI will use the newly raised capital to further develop its innovative compounds and technologies for the treatment of mental illness.
ATAI Life Sciences is a biotech company builder with offices in Berlin, New York and San Diego. The company’s mission is to bridge the gap between currently available, often inadequate therapies for mental illness and the needs of those affected with pioneering new technologies and agents. ATAI is active both in research and development and as an incubator. With the funds from the current Series C financing round, ATAI aims to achieve important clinical milestones for its drug pipeline for the treatment of chronic treatment-resistant depression, anxiety disorders and opioid addiction disorders, among others.
A Dentons team from Berlin, New York, Frankfurt and Munich provided ATAI Life Sciences with comprehensive advice on all aspects of the financing round. Corporate partner Thomas Schubert (Berlin; Picture) led the deal with support from Corporate partner Kristina Beirne in New York, Banking and Finance partner Oliver Dreher, partner Robert Weber, counsel Julia Sieber and associate David Hauser (all Frankfurt) as well as senior associate Dimitrios Andreadis in Munich (all Corporate).
The Latham team was led by London corporate partner Robbie McLaren and Frankfurt corporate partner Markus Krueger, with associates Jon Fox and David Funken.
Involved fees earner: Dimitrios Andreadis – Dentons; Kristina Beirne – Dentons; Oliver Dreher – Dentons; David Hauser – Dentons; Thomas Schubert – Dentons; Julia Sieber – Dentons; Robert Weber – Dentons; Jon Fox – Latham & Watkins; David Funken – Latham & Watkins; Markus Krüger – Latham & Watkins; Robbie McLaren – Latham & Watkins;
Clients: ATAI Life Sciences;